Our laboratory studies and develops adoptive T cell (CAR T cell) therapies targeting solid tumors. The postdoctoral scientist will develop genetically engineered T cell therapies starting from the molecular cloning phase of cell therapy development, and then advancing to preclinical in vitro work and clinically relevant mouse models. A strong background in molecular biology and immunology will allow the successful applicant to be creative within the lab, enhancing T cell function and tumor targeting for optimal patient translation and high impact publication. The postdoctoral scientist will work under the co-mentorship of Leonid Cherkassky and Renier Brentjens, as well as additional leaders in immune therapies within the Division for Translational Immuno-oncology (DTIO). We have a rapidly advancing program engaged in cutting edge preclinical science and supported by a strong institutional commitment to translating cellular therapies to cancer patients.
Requirements are a PhD or MD with background in Immunology or Molecular Biology. Experience with immune assays, FACS, cell culture, mouse experiments, cell transfections, PCR, and cloning and subcloning into vector constructs are very helpful. An enthusiasm for research investigation and strong work ethic are necessary.
Interested candidates should provide a CV highlighting previous research work, a brief (<1 page) personal statement, and 3 references. Inquiries and applications should be sent to Leonid Cherkassky, MD at Leonid.Cherkassky@RoswellPark.org.
Applications may also be sent to Leonid Cherkassky, MD, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, CSC P-641, Buffalo NY 14203.